Search results
Leading Cancer Center in Poland Announce Plans for a New State-of-the-Art BNCT Facility
TAE Life Sciences, a global leader in advanced biological-targeted radiation therapy, and creator of next-genera on boron neutron capture therapy (BNCT) systems, and the Franciszek Łukaszczyk Oncology Center (FLOC)
TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)
Developing targeted drugs for boron neutron capture therapy to treat refractory cancers
TAE Life Sciences is developing a next-generation boron neutron capture therapy for cancer. After recently introducing Alphabeam, a compact and affordable accelerator-based neutron system suitable for hospital settings, the company is now focusing on the development of novel boron drugs with improved tumor selectivity and increased 10B loads.
About TAE Life Sciences
About BNCT v3
TAE Life Sciences Adds Seasoned Chief Operating Officer to Scale New Radiation Treatment Platform
Robert Hill brings expertise in the technical and clinical development of radiation systems to speed platform research and commercialization.
Anna Theriault
BNCT Forum
TAE Life Sciences recently hosted an ESTRO webinar titled, “A New Era in Biologically-targeted Radiation Therapy for Cancer Treatment,” providing an overview of the state-of-the-art of accelerator-based boron neutron capture therapy (BNCT). The presentation also generated a robust discussion during the Q&A period. For those that missed the live event, we’ve distilled the most critical and insightful elements of both the presentation and discussion below:
Have questions about BNCT? Get answers on our new BNCT Forum